The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients

P. Breedveld; D. Pluim; G. Cipriani; P. Wielinga; O. van Tellingen; A.H. Schinkel; J.H.M. Schellens

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients

P. Breedveld, D. Pluim, G. Cipriani, P. Wielinga, O. van Tellingen, A.H. Schinkel, J.H.M. Schellens

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	2577-2582
Number of pages	2577
Journal	Cancer Research
Volume	65
Issue number	7
Publication status	Published - 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Breedveld, P., Pluim, D., Cipriani, G., Wielinga, P., van Tellingen, O., Schinkel, A. H., & Schellens, J. H. M. (2005). The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Research, 65(7), 2577-2582.

Breedveld, P. ; Pluim, D. ; Cipriani, G. et al. / The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. In: Cancer Research. 2005 ; Vol. 65, No. 7. pp. 2577-2582.

@article{052f3c8a47b04618ab7e98fd33324314,

title = "The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients",

author = "P. Breedveld and D. Pluim and G. Cipriani and P. Wielinga and \{van Tellingen\}, O. and A.H. Schinkel and J.H.M. Schellens",

year = "2005",

language = "Undefined/Unknown",

volume = "65",

pages = "2577--2582",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "7",

}

Breedveld, P, Pluim, D, Cipriani, G, Wielinga, P, van Tellingen, O, Schinkel, AH & Schellens, JHM 2005, 'The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients', Cancer Research, vol. 65, no. 7, pp. 2577-2582.

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. / Breedveld, P.; Pluim, D.; Cipriani, G. et al.
In: Cancer Research, Vol. 65, No. 7, 2005, p. 2577-2582.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients

AU - Breedveld, P.

AU - Pluim, D.

AU - Cipriani, G.

AU - Wielinga, P.

AU - van Tellingen, O.

AU - Schinkel, A.H.

AU - Schellens, J.H.M.

PY - 2005

Y1 - 2005

M3 - Article

SN - 0008-5472

VL - 65

SP - 2577

EP - 2582

JO - Cancer Research

JF - Cancer Research

IS - 7

ER -

Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (gleevec): Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Research. 2005;65(7):2577-2582.